Provided by Tiger Trade Technology Pte. Ltd.

CorMedix Inc.

8.28
+0.08000.98%
Post-market: 8.480.2000+2.42%18:05 EDT
Volume:1.01M
Turnover:8.43M
Market Cap:645.38M
PE:3.97
High:8.50
Open:8.28
Low:8.18
Close:8.20
52wk High:14.96
52wk Low:6.13
Shares:77.94M
Float Shares:66.02M
Volume Ratio:0.62
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.08
EPS(LYR):2.04
ROE:54.93%
ROA:24.56%
PB:1.40
PE(LYR):4.06

Loading ...

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

THOMSON REUTERS
·
Jul 29

Cormedix Names Elizabeth Hurlburt Chief Operating and Commercial Officer

Reuters
·
Jul 03

Cormedix Switches Auditor, Names Ernst & Young for 2026 Audit

Reuters
·
Jul 01

Cormedix Holds Annual Shareholder Meeting

Reuters
·
Jun 25

Raised 2026 Guidance and DefenCath Momentum Might Change The Case For Investing In CorMedix (CRMD)

Simply Wall St.
·
Jun 18

CorMedix announces United States Court of Appeals affirms patent judgements

TIPRANKS
·
Jun 08

Federal Circuit upholds CorMedix win in MINOCIN patent case against Nexus

Reuters
·
Jun 08

U.S. Court of Appeals for the Federal Circuit Affirms Victory for CorMedix Therapeutics in Minocin® Patent Litigation

THOMSON REUTERS
·
Jun 08

CorMedix - Federal Circuit Affirms Minocin Patents Valid and Infringed by Nexus Pharmaceuticals

THOMSON REUTERS
·
Jun 08

CorMedix to join RBC Capital Markets Global Healthcare Conference fireside chat

Reuters
·
May 15

RBC Capital Keeps Their Buy Rating on Cormedix (CRMD)

TIPRANKS
·
May 15

CorMedix Shares Climb With Higher 1Q Profit, Sales

Dow Jones
·
May 15

Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Cormedix (CRMD)

TIPRANKS
·
May 15

CorMedix Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

CorMedix Q1 net income rises to $38.6 million; revenue more than doubled to $127.4 million

Reuters
·
May 14

CorMedix reports Q1 EPS 43c, consensus 33c

TIPRANKS
·
May 14

CorMedix Q1 results beat on Defencath sales, raises outlook

Reuters
·
May 14

Cormedix Q1 Adj. EPS $0.43 Beats $0.36 Estimate, Sales $127.427M Beat $105.017M Estimate

Benzinga Earnings
·
May 14

CorMedix Inc - Raises FY 2026 Net Revenue Guidance to $325-$345 Mln; Adj Ebitda to $115-$135 Mln

THOMSON REUTERS
·
May 14

CorMedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
May 14